We find that 7 out of the 10 predicted targets (CHRM1, GRIN2A, ACHE, APP, PSEN1, BACE1, and APOE) show significant binding affinity (K_d ≤ 10 μM) to at least one AD drug, with the highest affinity observed between donepezil and ACHE (K_d = 0.02 μM). This evidence concerns the gene CHRM1 and Alzheimer disease.